Valuation: Neothetics Inc

Market Cap 1.02M 895K 846K 771K 1.44M 97.81M 1.45M 10.12M 3.92M 49.97M 3.83M 3.75M 161M P/E 2024
-0.08x
P/E 2025 26.7x
Enterprise Value 55.44M 48.65M 45.94M 41.87M 78.38M 5.31B 78.94M 550M 213M 2.71B 208M 204M 8.72B EV / Sales 2024
2.43x
EV / Sales 2025 2.76x
Free-Float
100%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 57 01/01/2018
Director of Finance/CFO 49 13/04/2023
Chief Operating Officer - -
Director TitleAgeSince
Chairman 57 -
Director/Board Member 67 01/01/2018
Director/Board Member 58 01/01/2018
Change 5-day change 1-year change 3-year change Capi.($)
-3.63%-6.12% - - 1.02M
+0.13%+2.65%+65.61%+114.28% 1,055B
+0.20%+0.46%+52.60%+69.24% 654B
-0.29%+0.14%+20.96%+70.93% 467B
-0.85%+0.98%+41.29%+44.38% 348B
+0.71%+4.08%+22.24%+29.51% 275B
+1.23%+0.42%+14.57%+12.13% 258B
+2.11%+7.51%+52.89%+55.37% 224B
+0.83%+0.55%+35.99%+101.70% 187B
0.00%-10.14%-29.94%-60.30% 171B
Average -0.04%+0.74%+30.69%+48.58% 404.26B
Weighted average by Cap. +0.02%+1.32%+41.54%+67.83%

Financials

2024 2025
Net sales 19.36M 16.99M 16.05M 14.62M 27.38M 1.86B 27.57M 192M 74.38M 948M 72.7M 71.13M 3.05B 20.18M 17.71M 16.73M 15.24M 28.53M 1.93B 28.74M 200M 77.53M 988M 75.78M 74.14M 3.18B
Net income -8.86M -7.77M -7.34M -6.69M -12.53M -849M -12.62M -87.87M -34.03M -434M -33.27M -32.55M -1.39B 391K 343K 324K 295K 553K 37.48M 557K 3.88M 1.5M 19.15M 1.47M 1.44M 61.53M
Net Debt 45.84M 40.22M 37.99M 34.62M 64.81M 4.39B 65.27M 455M 176M 2.24B 172M 168M 7.21B 54.42M 47.75M 45.1M 41.1M 76.94M 5.22B 77.48M 540M 209M 2.66B 204M 200M 8.56B
Logo Neothetics Inc
Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company. The Company is commercializing its products to address unmet needs in women’s sexual and reproductive health. The Company’s first approved product, PHEXXI (lactic acid, citric acid, and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of over 12 pre-filled applicators and is applied 0-60 minutes before each act of intercourse. PHEXXI is a gel that works to prevent pregnancy without the use of hormones. PHEXXI prevents pregnancy by reducing sperm motility, inhibiting sperm from reaching the ovum to form a zygote. Using the PHEXXI telehealth platform, women can directly meet with a health care provider to determine their eligibility for a PHEXXI prescription. The Company also commercialized SOLOSEC (secnidazole) 2g oral granules, an antibiotic for the treatment of two sexual health diseases such as bacterial vaginosis and trichomoniasis.
Employees
-